Iranian Model of Renal Allograft Transplantation In 3028 Recipients: Survival and Risk Factors

Einollahi, Behzad; Pourfarziani, Vahid; Ahmadzad-Asl, Masoud; Davoudi, Farnoush; Lessan-Pezeshki, Mahbob; Davoudi, Amir; Nourbala, A.; Shariat-Moghani, S.; Nemati, Eghlim; Poorrezagholi, Fatemeh; Simforoosh, N.

doi:10.1016/j.transproceed.2007.03.033

Cited by 18 publications

(13 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This confirms that a possible relatively lower average survival for our patients could not rationalize the observed low incidence of PTLD in our patients. Moreover, according to our previous studies, mean survival time for our patients was not lower than that reported from other countries [20].…”

Section: Discussionsupporting

confidence: 68%

Lymphoma after living donor kidney transplantation: an Iranian multicenter experience

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 68%

Lymphoma after living donor kidney transplantation: an Iranian multicenter experience

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: An Investigation Was Conducted Involving 255 Renal Transplanmentioning

confidence: 99%

“…Patients with chronic kidney disease are at an increased risk for acquiring HCV either because of their frequent exposure to blood from transfusions, or by exposure to HCV by nosocomial transmission, either during hemodialysis or at the time of renal transplantation. HCV infection has been established as a factor in reduced patient and graft survivals following renal transplantation (Meyers et al 2003, Aroldi et al 2005, Fabrizi et al 2005, Pedroso et al 2006, Einollahi et al 2007.The determination of alanine aminotransferase (ALT) levels as well as HCV RNA tests have been utilized in both the diagnosis and follow-up of patients with HCV infection. The latter also plays an important role in monitoring the virological response to antiviral treatment in addition to HCV genotype determination, which is a relevant predictive parameter of the response to treatment; it is thus used for selecting therapeutic regimens (Scott & Grech 2007).…”

mentioning

confidence: 99%

Epidemiological aspects of hepatitis C virus infection among renal transplant recipients in Central Brazil

Botelho

Ferreira²,

Reis³

et al. 2008

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

An investigation was conducted involving 255 renal transplant recipients in the state of Goiás, Central Brazil, to determine the prevalence of hepatitis C virus (HCV), its risk factors, the genotypes involved, and the level of alanine aminotransferase (ALT) present in the patients. All serum samples were tested for anti-HCV antibodies and HCV RNA. Hepatitis C virus (HCV) is a well-known agent of liver diseases, including chronic hepatitis, cirrhosis, and hepatocellular carcinoma (Chen & Morgan 2006). Patients with chronic kidney disease are at an increased risk for acquiring HCV either because of their frequent exposure to blood from transfusions, or by exposure to HCV by nosocomial transmission, either during hemodialysis or at the time of renal transplantation. HCV infection has been established as a factor in reduced patient and graft survivals following renal transplantation (Meyers et al. 2003, Aroldi et al. 2005, Fabrizi et al. 2005, Pedroso et al. 2006, Einollahi et al. 2007.The determination of alanine aminotransferase (ALT) levels as well as HCV RNA tests have been utilized in both the diagnosis and follow-up of patients with HCV infection. The latter also plays an important role in monitoring the virological response to antiviral treatment in addition to HCV genotype determination, which is a relevant predictive parameter of the response to treatment; it is thus used for selecting therapeutic regimens (Scott & Grech 2007). This virus is classified into six genotypes (1-6), each comprising multiple subtypes (designated a, b, c, etc). These genotypes have distinct geographical distributions. Furthermore, the genotyping of HCV isolates is a useful tool for establishing the source of outbreaks in hemodialysis centers and other nosocomial settings (Zein 2000, Simmonds et al. 2005). The prevalence of HCV infection has been reported to range from 7.2% among renal transplant recipients (RTP) in Switzerland to 63.8% in Saudi Arabia (Mitwalli et al. 2006, Fehr et al. 2003. In Brazil, a continental country, epidemiological data concerning HCV infection in renal transplant patients are still rare (Corrêa et al. 2003, Giordano et al. 2003, and little is known about the genetic diversity of HCV isolates in these patients (Giordano et al. 2003, Perez et al. 2003. In this study, the prevalence of HCV infection among RTP in Central Brazil was estimated and risk factors associated with HCV infection in this population were analyzed. In addition, ALT levels and HCV genotypes were determined in these patients. PATIENTS, MATERIALS AND METHODSPatients -This study was carried out in the Santa Casa de Misericórdia in Goiânia city, the largest renal transplantation unit in the state of Goiás (GO), Central Brazil. A pilot study found a prevalence of 16% for anti-HCV. In this investigation, the sample was calculated according to the size of the population (420 RTP), on the basis of an alpha error of 5%, a power of 80%, an expected HCV prevalence of 16% and a precision of 3%. In accordance with these data, the minimum sample s...

show abstract

“…Furthermore, the infection is known as a factor in mortality and graft loss after renal transplantation (10)(11)(12)(13)(14). Tragically, despite the screening of blood products for HCV, the disease is still frequent among the patients with end-stage renal disease in both developed and less-developed countries (15).…”

Section: Introductionmentioning

confidence: 99%

Hepatitis C Virus Load in Seropositive Liver and Kidney Transplant Recipients by Quantitative Real-Time PCR Before and After Transplantation

Behzadi

Ziyaeyan

2013

Jundishapur J Microbiol

View full text Add to dashboard Cite

Background: Hepatitis C virus (HCV) infection is one the major health concern among the infected transplant patients. Considering several complications of the disease in them, pre and post-transplantation studies should be performed for monitoring of the infection, as well as, developing new treatment protocols. Objectives: The current study was conducted to determine the Hepatitis C Virus RNA level among seropositive liver and kidney transplant recipients in Namazi Hospital; the main transplantation center in southern Iran. Materials and Methods: RNAs were extracted from 105 serum samples of seropositive liver and kidney transplant recipients and analyzed by Real-time PCR assay using a set of primers. Results: HCV RNA was detected in a total of 46/105 (43.8%) recipients' serum samples [39/46 (84.8%) males and 7/46 (15.2%) females]. Moreover, 8/46 (17.4%) and 38/46 (82.6%) were kidney and liver recipients, respectively. The copy number of HCV RNA, measured by the Real-time PCR assay, ranged from 5 × 102 to 3.14 × 109 copies/mL; Median 2.37 × 105 copies/mL and 1.7 × 103 to 9.44 × 104 copies/mL; Median 2.89 × 104 copies/ mL in liver and renal transplant patients, respectively. The comparison of viral load between liver pre transplant recipients group and post transplant counterpart indicated that the copy number of HCV RNA was significantly higher in the post transplant recipients (P = 0.033). The prevalence of the viral nucleic acid was significantly higher in males than in females (P = 0.026). Similarly, with regards to the age groups, the prevalence of HCV RNA was significantly higher in age group ≥ 45 years than age group < 45 years (P = 0.028). Conclusions: Considering the results, it can be concluded that HCV RNA detection is strongly suggested in transplant patients group to determine the prevalence of the disease and their responses to antiviral therapy and diagnosis of drug resistance. In addition, continuous and regular surveillance of HCV RNA level in such patients is highly recommended in order to better manage the complications of graft loss and reduce the mortality rate. Further studies are needed to find new therapeutic methods to lower the incidence of infection of new healthy allograft tissues in HCV RNA positive recipients.

show abstract

Iranian Model of Renal Allograft Transplantation In 3028 Recipients: Survival and Risk Factors

Cited by 18 publications

References 16 publications

Lymphoma after living donor kidney transplantation: an Iranian multicenter experience

Lymphoma after living donor kidney transplantation: an Iranian multicenter experience

Epidemiological aspects of hepatitis C virus infection among renal transplant recipients in Central Brazil

Hepatitis C Virus Load in Seropositive Liver and Kidney Transplant Recipients by Quantitative Real-Time PCR Before and After Transplantation

Contact Info

Product

Resources

About